[1] Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst,2008,100:698-711. .
[2] Llovet JM, Ricci S, Mazzaferro V,et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008,359:378-390. .
[3] Mushti SL, Mulkey F, Sridhara R. Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials. Clin Cancer Res,2018,24:2268-2275. .
[4] Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stiflfles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg,2014,140:1225-1236. .
[5] Lencioni R, Llovet JM. Modifified RECIST (mRECIST) assess-ment for hepatocellular carcinoma. Semin Liver Dis,2010,30:52-60. .
[6] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in fifirst-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet,2018,391:1163-1173. .
[7] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 2017,389:2492-2502. |
